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Abstract
Background: Published research on depression among people living with HIV/AIDS (PLWHA) from Africa is
increasing, but data from Kenya remains scarce. This cross-sectional study measured the prevalence and correlates
of depressive symptoms among PLWHA in rural Kilifi, on the Kenyan coast.
Methods: Between February and April 2018, we consecutively recruited and interviewed 450 adults living with HIV
and on combination antiretroviral therapy (cART). Depressive symptoms were assessed with the 9-item Patient
Health Questionnaire (PHQ-9), with a positive depression screen defined as PHQ-9 score ≥ 10. Measures of
psychosocial, health, and treatment characteristics were also administered.
Results: The overall prevalence of depressive symptoms was 13.8% (95% Confidence Interval (95%CI): 10.9, 17.3).
Multivariable logistic regression analysis identified current comorbid chronic illness (adjusted Odds Ratio (aOR) 5.72,
95% CI: 2.28, 14.34; p < 0.001), cART regimen (aOR 6.93, 95%CI: 2.34, 20.49; p < 0.001), perceived HIV-related stigma
(aOR 1.10, 95%CI: 1.05, 1.14, p < 0.001) and difficulties accessing HIV care and treatment services (aOR 2.37, 95%CI:
1.14, 4.91; p = 0.02) as correlates of depressive symptoms.
Conclusion: The prevalence of depressive symptoms among adults living with HIV on the Kenyan coast is high.
Those at high risk for elevated depressive symptoms (e.g., with comorbid chronic illnesses, on second-line cART,
experiencing perceived HIV-stigma or with problems accessing HIV care) may benefit from early identification,
treatment or referral, which requires integration of mental health programmes into HIV primary care.
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Introduction
Depression remains a common mental disorder [1] and is
projected to be the leading cause of disease burden world-
wide by the year 2030 [2]. This neuropsychiatric disorder
occurs two to three times higher in people living with
HIV/AIDS (PLWHA) than in the general population [3,
4]. In low resourced settings of sub-Saharan Africa (SSA),
where HIV/AIDS burden is enormous [5], prevalence of
depressive symptoms is high; ranging from 14 to 32% in
PLWHA on combination antiretroviral therapy (cART),
and between 9 and 31% in mixed/untreated groups [4]. In
Kenya, studies conducted among PLWHA have reported
prevalence of major depressive disorder as 32% [6] and
other depressive disorders as 15% [7].
Depression has deleterious consequences on the wellbeing
and overall health of PLWHA. It may lead to alteration of
economic productivity [8], reduced cART adherence [9],
and poor quality of life [10]. Studies from SSA reported that
depression is associated with poorer overall health status
[11], increases the risk for suicidality [12], leads to faster dis-
ease progression and increased mortality [8].
Two recent studies have systematically reviewed the
literature on correlates of depression among PLWHA
within the SSA setting. One focused broadly on studies
conducted within SSA [4], while the other specifically
targeted studies conducted in Ethiopia [13]. Only one
study [14] in the former review by Bernard et al. [4]
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contained data from Kenya, and the authors combined
this data with data from Tanzania and Namibia in their
analyses. From the reviewed studies, sociodemographic
factors such as increasing age, not being married, low
levels of education, unemployment, and lower income
were significant correlates of depressive symptoms in
PLWHA on cART. Psychosocial factors such as per-
ceived HIV-related stigma and poor social support also
consistently correlated with depressive symptoms. In-
consistent findings are reported on gender and cluster of
differentiation 4 (CD4) cell count as correlates of depres-
sive symptoms in both reviews.
Depression is a common neuropsychiatric disorder in
PLWHA but has been neglected in SSA for a long time
[8]. Noteworthy is that since 2010, the number of pub-
lished reports on depression among PLWHA in Africa is
increasing [4]. However, such research from Kenya, par-
ticularly the coastal region, remains limited. The only
studies we are aware of, that have extensively looked
into depression among PLWHA at the Kenyan coast, are
those by Secor et al. [7] and Korhonen et al. [15], but
these studies, focussed on key population of men who
have sex with men. The present study, therefore, aimed
to determine the prevalence of depressive symptoms and




This cross-sectional study was conducted in Kilifi
County – coastal Kenya, between February and April
2018, through the Centre for Geographic Medicine Re-
search (CGMR). Kilifi County consists mostly of a rural
population. Majority of its residents are poor (71.4% live
below poverty line), lack adequate formal education
(only 7.1% have attained secondary education) and earn
a living mainly through subsistence farming or fishing
[16, 17]. Adult HIV prevalence is estimated at 5%, al-
most near the national average prevalence of 6% [18].
The socio-economic disparities in this setting may have
a role to play in HIV infection and prognostic patterns.
A public hospital – Kilifi County Hospital – from where
participants were recruited, has a specialized HIV care
and treatment clinic that was established in 2003. This
HIV clinic provides comprehensive care services (includ-
ing medical reviews, counselling, family planning, nutri-
tional care, and antiretroviral dispensary) to PLWHA
and serves as a research facility. About 60 patients are
seen daily. To date, the clinic has enrolled over 9000 pa-
tients of all ages.
Study participants
This work is part of data collected from a larger project
looking at different outcomes in adults living with HIV,
including health-related quality of life and mental health.
Participants were patients attending an HIV care and
treatment clinic at Kilifi County Hospital. To be in-
cluded in the study, participants had to be adults, 18 to
60 years old, with confirmed HIV positive status, on
cART, and providing consent for participation. We ex-
cluded participants who did not meet the inclusion cri-
teria above. We did not include elderly individuals living
with HIV (above 60 years) because of the increased like-
lihood of illnesses associated with advancing age, that
may have an impact on the quality of life [19]. Eligible
participants were also excluded if they could not com-
prehend and/or communicate in the national language,
Kiswahili, which was used during the administration of
all study instruments.
Sampling and sample size estimation
Selection was done through consecutive sampling of eli-
gible patients on arrival at the clinic until the required
sample size was achieved. Sample size calculation was
determined using the single population proportion for-
mula. With precision set at 3.5% around a previously re-
ported prevalence of 15.5% for depressive symptoms
among adults living with HIV [20], a sample of 410 par-
ticipants or more would give reliable prevalence esti-
mates. To cater for a 10% non-response or systematic
missing of data, non-contact, or other factors that tend
to reduce the final sample size, we considered a sample
of 450 as sufficient. This sample is > 95% powered to de-
tect a proportion of ≥0.10 given a null proportion of
0.05 at 5% level of significance.
Data collection procedures
For all participants, study instruments were interviewer-
administered via android tablets, in the same order, and
under the same administration environment. Research
assistants received a 4-day training in research ethics
and good interviewing techniques (with role plays) and
were taught how to administer the tablet-based ques-
tionnaires. Questionnaire administration was done in a
private and quiet room within the clinic setting, and the
entire interview session lasted between 30 to 45min.
Measures
Depressive symptoms The 9-item Patient Health Ques-
tionnaire (PHQ-9) [21] was administered as a measure
of depressive symptoms. This was preferred as it has
been considered a reliable depression screening tool
when used with PLWHA in Kenya [22], Uganda [23],
and South Africa [23]. Also, recent guidelines from
Kenya’s Ministry of Health [24] recommending screen-
ing for depressive symptoms with PHQ-9 in the routine
care of patients on cART informed the choice of this
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measure. All the 9 PHQ items are rated on a Likert scale
of “0” (not at all) to “3” (nearly every day), with the
scores summated to derive a total score that ranges from
0 to 27. In terms of severity of depressive symptoms,
scores of 5–9 points, 10–14 points, 15–19 points, and
20–27 points indicate, respectively, mild, moderate,
moderately severe, and severe levels of depressive
symptoms. Consistent with previous studies from SSA
[23, 25, 26], a cut-off score of ≥10 was used in the
present study to define a positive depression screen in
the respondents. In SSA setting and with the adult HIV-
population, this cut-off value provides the best combin-
ation of sensitivity (91.7%) and specificity (89.0%) [23].
PHQ-9 has previously been found to have good internal
consistency (Cronbach’s alpha = 0.78) and acceptable
test-retest reliability (intra-class correlation coefficient
[ICC] = 0.59) when used among PLWHA in Kenya [22].
In this study, PHQ-9 internal consistency alpha was 0.81
(95% confidence interval [95% CI]: 0.78, 0.84) with a
test-retest reliability of 0.78 (95% CI: 0.63, 0.87).
Sociodemographic and asset index items
A researcher-developed sociodemographic questionnaire
was used to capture participant’s age, sex, marital status,
educational level, employment status, and people with
whom they were living with. Additionally, an asset index
form previously used in this setting [10] was used to
gather information on disposable assets owned by partic-
ipants as an indicator of their socioeconomic status.
Health-related characteristics
During the face-to-face interviews, participants self-
reported about current history of smoking, khat or alco-
hol use, and presence of any current opportunistic infec-
tion or chronic illness (that they were made aware of by
their clinician) using “0” (no) or “1” (yes) response
options.
Treatment-related characteristics
In the interviews, participants were also asked about dis-
closure (if they had disclosed their seropositive status or
not), their satisfaction with the current level of care (sat-
isfied or not) and their perception on clinic accessibility
(if current HIV-clinic was accessible or not). In respond-
ing to the latter item, participants were asked to con-
sider the distance between where they were living and
the location of the HIV-clinic.
Clinical information
A clinical record form was used to extract participant
data from the clinic’s medical record database on: dates
of HIV-diagnosis and cART initiation, most recent
cART regimen, World Health Organization (WHO) clin-
ical staging, viral load, CD4 cell count, height and weight
(for Body Mass Index [BMI]) calculation). We used
patient-unique clinic numbers to access the medical re-
cords of our study participants. All participants gave in-
formed consent for this clinical information to be
retrieved from their clinic medical records.
HIV-related stigma
The 12-item HIV stigma scale [27] was used to assess
patient perceived HIV-related stigma under four dimen-
sions of i) personalised stigma; ii) disclosure concerns;
iii) negative self-image; and iv) concerns with public atti-
tudes. Items on this scale are rated as “1” (strongly dis-
agree), “2” (disagree) “3” (agree) and “4” (strongly agree).
A total score derived from summated item scores ranges
between 12 and 48. Higher scores indicate a greater level
of perceived HIV-related stigma. In its initial validation,
Cronbach’s alpha was > 0.7 [27]. In the present study
Cronbach’s alpha was 0.81 (95% CI: 0.78, 0.83).
Statistical analysis
Frequencies (with percentages) and means (with standard
deviations) were used to describe sample characteristics.
Departure from linearity in continuous variables was
checked through visual inspection of the frequency histo-
gram with normal overlay graph. Prevalence was pre-
sented as percentages. Univariate logistic regression
analysis was used to assess the crude association between
sample characteristics and positive depression screen
(PHQ-9 cut-off score ≥ 10). Multivariable logistic regres-
sion analysis was used to investigate factors independently
associated with a positive depression screen. Since there is
no universal consensus in selecting predictor variables, we
included all variables with p ≤ 0.20 from univariate logistic
regression analysis in multivariable analysis. Bursac et al.
[28] suggest that p-values less than 0.25 in univariate lo-
gistic regression may indicate some reasonable association
with the outcome. Backward stepwise logistic regression
models were fit in the multivariable model building
process, removing all variables with p > 0.05 (one at a
time). Age and sex were included regardless of the p-value
as these have been reported to be associated with depres-
sive symptoms in other studies from SSA [4, 6, 13, 14]. Re-
gression diagnostics for correlation of covariates were
performed, with no collinearity problems identified. For
the final model, Hosmer-Lemeshow goodness of fit statis-
tic (p-value > 0.05) was considered a well-fitting logistic
regression model. All analyses were conducted in STATA
(V.14.0) statistical software package [29] with p < 0.05 con-
sidered statistically significant for all tests of hypothesis.
Results
Sample characteristics
In total, 512 adult patients attending an HIV care and
treatment clinic at Kilifi County Hospital were approached
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to participate in this study. Forty-four patients declined to
participate after the study was explained to them in de-
tails. Eighteen patients were excluded because they were
over 60 years (n = 11) or were unable to comprehend and/
or communicate in Kiswahili (n = 7). Consequently, 450
patients, hereafter referred to as study participants, were
consecutively recruited.
Table 1 presents sample characteristics aggregated by
depressive symptom. Overall, the mean age of the partic-
ipants was 42.7 (SD = 9.7) years. Most study participants
were female (79.1%), had attained primary level educa-
tion (53.1%), were unemployed (59.8%) and lived with a
family member (82.4%). Only 12.7% of study participants
were never married. A small proportion of study partici-
pants currently smoked (9.8%), used khat (4.4%) and
were taking alcohol (11.4%). Chronic illnesses comorbid
with HIV was present in 8.2% of the study participants,
hypertension being the commonest (n = 20). The mean
BMI of study participants was within the normal range
(mean [SD] = 22.4 [4.8]). Most study participants were
on first-line cART regimen (95.3%), and in stage 1 of the
WHO clinical staging (93.7%). Only 6.0% of study partic-
ipants had not disclosed their seropositive status. Less
than a quarter of study participants (18.4%) had an op-
portunistic infection at the time of interview. Most par-
ticipants found the HIV care and treatment clinic easily
accessible (86.2%) and were generally satisfied with the
current level of care they were receiving (95.8%).
Prevalence of depressive symptoms and severity
Using PHQ-9 cut-off score of ≥10, which has been shown
to maximize on sensitivity and specificity for depression
screening [23]; the overall prevalence of depressive symp-
toms was 13.8% in this sample. In terms of severity of de-
pressive symptoms in the sample, 23.8% had mild, 9.6%
had moderate, 3.6% had moderately severe, and 0.7% had
severe depressive symptoms (Table 2).
Factors associated with depressive symptoms among
adults living with HIV from coastal Kenya
Tables 1 and 3 present the results following univariate
and multivariable logistic regression analyses for factors
associated with positive depression screen among adults
receiving cART in Kilifi. Even though viral load was as-
sociated with positive depression screen at p = 0.20 in
univariate analysis (Table 1), we did not include this
variable in the multivariable logistic regression model
because many patients had missing values (n = 145). For
all our study participants, we did not find any current
records of CD4 cell count. Few participants had baseline
CD4 data (when they were being enrolled to the clinic).
Therefore, logistic regression analyses did not include
CD4 cell count information.
In the univariate logistic regression analyses, increas-
ing perceived HIV-related stigma, being separated or di-
vorced or widowed, on second-line cART regimen,
having any current chronic illness or opportunistic infec-
tion and clinic inaccessibility were significantly associ-
ated with an increased risk for positive depression
screen (p < 0.05; Table 1). Having no education or sec-
ondary education (relative to tertiary), living with a rela-
tive/friend (relative to family), and increased duration
since HIV diagnosis were all reasonably associated with
a positive depression screen at p ≤ 0.20. With increasing
BMI, the risk of positive depression screen was 6% less
likely at p = 0.11 (Table 1). All these variables were
added to the multivariable logistic regression modelling
in addition to age and sex (forced variables).
In the final multivariable analysis, factors that were sig-
nificantly associated with positive depression screen
among adults receiving cART in Kilifi included: having a
current chronic illness (p < 0.001), being on second-line
cART regimen (p < 0.001), clinic inaccessibility (p = 0.02),
and increasing perceived HIV-related stigma (p < 0.001)
(Table 3). The cross-validated mean area under the curve
(cvMean AUC) for the final multivariable model was 0.75
(bootstrap bias corrected 95% CI: 0.66, 0.80).
Discussion
We report a relatively high prevalence of depressive symp-
toms (13.8, 95% CI: 10.9, 17.3) among PLWHA on cART
on the Kenyan coast. We found that the presence of any
chronic illness, being on second-line cART treatment, per-
ceived HIV-related stigma, and problems of accessing
HIV-related services among our study participants were
significant correlates of positive depression screen.
The reported prevalence is considerably higher than the
national prevalence of depression in Kenya of 4.4% [1],
but is similar to estimates (ranging between 11 to 16%,
with their respective 95% confidence intervals around our
estimate) reported from studies conducted among
PLWHA in Ethiopia [20, 30, 31], Rwanda [32], and
Uganda [33]. However, the prevalence estimate in our
study was much lower than what is reported in other
studies from SSA such as Endeshaw et al. [34] in Ethiopia
(60%), Kitshoff and Naidoo [35] in South Africa (62%),
L’akoa et al. [36] in Cameroon (63%), and Shittu et al. [37]
in Nigeria (57%). This could be due to differences in sam-
ple size, study population (selection bias), or tools used
across studies. Analysis of findings reported by Endeshaw
et al. [34] only involved a sample size of 55 participants.
Kitshoff and Naidoo [35] used the Center for Epidemio-
logic Studies -Depression Scale (CES-D) to screen for de-
pressive symptoms. The study by L’akoa et al. [36] was on
newly diagnosed HIV patients, who are twice as likely than
the general population of PLWHA to be depressed [38].
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Table 1 Participant characteristics by depressive symptoms and associated crude odd ratios
Sample Characteristic Total
sample
Positive depression screen Unadjusted ORs
No Yes* ORs (95% CI) p-value #
Sociodemographic characteristics
Age – years, mean (SD) 42.7 (9.7) 42.9 (9.8) 41.6 (9.4) 0.99 (0.96, 1.01) 0.34
Sex
Female 356 (79.1) 304 (78.4) 52 (83.9) Ref
Male 94 (20.9) 84 (21.7) 10 (16.1) 0.70 (0.34, 1.43) 0.32
Marital status
Married/cohabiting 196 (43.6) 177 (45.6) 19 (30.7) Ref
Separated/Divorced/Widowed 197 (43.8) 160 (41.2) 37 (59.7) 2.15 (1.19, 3.90) 0.01
Never married 57 (12.7) 51 (13.1) 6 (9.7) 1.10 (0.42, 2.89) 0.85
Education
Tertiary 22 (4.9) 21 (5.4) 1 (1.6) Ref
Secondary 66 (14.7) 55 (14.2) 11 (17.7) 4.20 (0.51, 34.57) 0.18
Primary 239 (53.1) 208 (53.6) 31 (50.0) 3.13 (0.41, 24.10) 0.27
None 123 (27.3) 104 (26.8) 19 (30.7) 3.84 (0.49, 30.25) 0.20
Employment
Formally employed 53 (11.8) 47 (12.1) 6 (9.7) Ref
Self-employed 117 (26.0) 101 (26.0) 16 (25.8) 1.24 (0.46, 3.37) 0.67
Other 11 (2.4) 10 (2.6) 1 (1.6) 0.78 (0.08, 7.24) 0.83
Unemployed (including students) 269 (59.8) 230 (59.3) 39 (62.9) 1.33 (0.53, 3.32) 0.54
Currently living with
Family 371 (82.4) 320 (82.5) 51 (82.3) Ref
Relative/friend 10 (2.2) 7 (1.8) 3 (4.8) 2.69 (0.67, 10.74) 0.16
Alone 69 (15.3) 61 (15.7) 8 (12.9) 0.82 (0.37, 1.82) 0.63
Asset index score a – mean (SD) 1.2 (1.4) 1.3 (1.4) 1.1 (1.2) 0.89 (0.72, 1.10) 0.27
Perceived HIV-stigma score b – mean (SD) 28.4 (7.7) 27.7 (7.4) 32.9 (8.0) 1.09 (1.05, 1.13) < 0.001
Health characteristics
Currently smoking, OM = 1
No 405 (90.2) 351 (90.7) 54 (87.1) Ref
Yes 44 (9.8) 36 (9.3) 8 (12.9) 1.44 (0.64, 3.27) 0.38
Current use of khat
No 430 (95.6) 369 (95.1) 61 (98.4) Ref
Yes 20 (4.4) 19 (4.9) 1 (1.6) 0.32 (0.04, 2.42) 0.27
Current alcohol use, OM = 1
No 398 (88.6) 346 (89.4) 52 (83.9) Ref
Yes 51 (11.4) 41 (10.6) 10 (16.1) 1.62 (0.77, 3.44) 0.21
Any current chronic illness
No 413 (91.8) 363 (93.6) 50 (80.7) Ref
Yes $ 37 (8.2) 25 (6.4) 12 (19.4) 3.48 (1.65, 7.37) < 0.001
Clinical characteristics
BMI – kg/m2, mean (SD), OM = 4 22.4 (4.8) 22.5 (4.8) 21.5 (4.6) 0.95 (0.89, 1.01) 0.11
cART regimen, OM = 4
First line 425 (95.3) 372 (96.6) 53 (86.9) Ref
Second line 1 21 (4.7) 13 (3.4) 8 (13.1) 4.32 (1.71, 10.91) < 0.001
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Shittu et al. [37] recruited both cART-experienced and
cART-naïve patients.
In primary health care of most low resourced settings,
depression is under-diagnosed and under-treated [8, 26].
In Kenya, and by extension similar low-resourced set-
tings of SSA, poor integration of mental health services
in primary care [39], scarcity of specialized mental health
personnel [40], and a lack of mental health knowledge
among primary health care staff [40] constitute barriers
to the adequate identification, treatment or referral of
those with mental health issues. Such barriers may con-
tribute to the existence of relatively high levels of de-
pressive symptoms among PLWHA reported in our
study, but also in other studies from SSA.
In trying to address the burden of depression among
PLWHA in SSA, calls were made to integrate mental
health services in routine HIV care [8, 41]. In Kenya, as
Table 1 Participant characteristics by depressive symptoms and associated crude odd ratios (Continued)
Sample Characteristic Total
sample
Positive depression screen Unadjusted ORs
No Yes* ORs (95% CI) p-value #
Viral load, OM = 145
≤ 1000 copies/mL 265 (86.9) 232 (87.9) 33 (80.5) Ref
> 1000 copies/mL 40 (13.1) 32 (12.1) 8 (19.5) 1.76 (0.75, 4.14) 0.20
WHO clinical stage, OM = 5
Stage 1 417 (93.7) 360 (93.8) 57 (93.4) Ref
Stage 2 22 (4.9) 18 (4.7) 4 (6.6) 1.40 (0.46, 4.30) 0.55
Stage 3 3 (0.7) 3 (0.8) 0 (0.0) – –
Stage 4 3 (0.7) 3 (0.8) 0 (0.0) – –
Months since HIV diagnosis – mean (SD) 96.8 (50.2) 95.4 (50.7) 105.5 (46.1) 1.00 (1.00, 1.01) 0.14
Months since cART initiation – mean (SD) 81.9 (47.1) 81.1 (47.4) 86.7 (45.2) 1.00 (1.00, 1.01) 0.38
Treatment characteristics
HIV status disclosure
Yes 423 (94.0) 364 (93.8) 59 (95.2) Ref
No 27 (6.0) 24 (6.2) 3 (4.8) 0.77 (0.23, 2.64) 0.68
Any current opportunistic infection
No 367 (81.6) 323 (83.2) 44 (71.0) Ref
Yes 83 (18.4) 65 (16.8) 18 (29.0) 2.03 (1.10, 3.74) 0.02
Clinic accessibility, OM = 2
Yes 386 (86.2) 340 (88.1) 46 (74.2) Ref
No 62 (13.8) 46 (11.9) 16 (25.8) 2.57 (1.35, 4.91) < 0.001
Satisfaction with current care, OM = 1
Yes 430 (95.8) 371 (95.9) 59 (95.2) Ref
No 19 (4.2) 16 (4.1) 3 (4.8) 1.18 (0.33, 4.17) 0.80
Notes: * cut-off score ≥ 10 on PHQ-9 # based on the Wald’s test $ one or more chronic illness in addition to HIV. Hypertension (54.1%), diabetes and cancer (8.1%
each), kidney disease (2.7%), others (27.0%). 1 - all the participants were initially started on first line cART but at the time of data collection, the regimen had
changed to second line. ORs odd ratios, SD standard deviation, Ref reference category, OM observation with missing value, a score range = 0 to 7, b score range =
12 to 48, WHO world health organization, cART combination antiretroviral therapy, BMI body mass indexNotes: *cut-off score ≥ 10 on PHQ-9 # based on the Wald’s
test $ one or more chronic illness in addition to HIV. Hypertension (54.1%), diabetes and cancer (8.1% each), kidney disease (2.7%), others (27.0%). 1 - all the
participants were initially started on first line cART but at the time of data collection, the regimen had changed to second line. ORs odd ratios, SD standard
deviation, Ref reference category, OM observation with missing value, a score range = 0 to 7, b score range = 12 to 48, WHO world health organization, cART
combination antiretroviral therapy, BMI body mass index
Table 2 Prevalence of depressive symptoms
Distribution
(n out of N = 450)
Prevalence (95% CI)
Severity of depressive symptoms
Mild 107 23.8 (20.1, 27.9)
Moderate 43 9.6 (7.2, 12.7)
Moderately severe 16 3.6 (2.2, 5.7)
Severe 3 0.7 (0.2, 2.1)
Positive depression screen (cut-off score≥ 10)
Yes 62 13.8 (10.9, 17.3)
Notes: 95% CI - 95% confidence interval
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of 2016, strides were made to develop guidelines [24] in
which screening for depression is recommended as a
core aspect of HIV care. Under the new guidelines,
healthcare providers at the HIV clinics are required to
assess for depressive symptoms using the PHQ-9. How-
ever, national implementation of such guidelines re-
mains a key challenge, and this is perhaps the case in
other similar settings. To successfully integrate mental
health screening into HIV primary care in our setting
and similar settings, we call for the training of healthcare
providers at HIV clinics on detection, management of,
or referral for common mental health problems. Early
detection will facilitate early management or referral for
specialized care, hence better outcomes.
It has been observed that a growing number of adults
in their 40s and 50s with long-term HIV and treatment
histories are experiencing concurrent chronic diseases
related to premature aging [42], similar to the multi-
morbidity common in elderly populations [43]. In this
study, the mean age of participants was 42.7 years, and
duration on cART averaged 82months (about 7 years).
Using this sample, participants living with HIV and co-
morbid chronic illness (one or more chronic illness in
addition to HIV) had nearly 6-times higher odds of a
positive depression screen than those without any
chronic illness. Our finding resonates with findings from
a study conducted in the United States (US) among
PLWHA 18 years old or above [44]. Uebelacker et al.
[44] found that participants with moderate-severe
chronic pain had higher levels of depressive symptoms
relative to those with no chronic pain (OR 1.13, 95% CI:
1.07, 1.20). In PLWHA, additional comorbid chronic ill-
ness may limit an individual’s mobility, independence or
make it impossible for one to pursue activities they usu-
ally enjoy leading to signs of despair, sadness, and loss of
hope in the future manifesting as depressive symptoms.
We asked our participants about accessibility of the
HIV clinic they were currently attending, by asking them
to consider the distance between where they lived and
the current location of the clinic. Less than a quarter of
the participants (14%) found the clinic inaccessible, and
this was significantly associated with higher odds of a
positive depression screen. We presume that participants
who found the HIV clinic inaccessible live in remote
areas of Kilifi County and must travel long distances to
access HIV-related services. Costs of travelling back and
forth among other factors may hinder regular clinic
attendance. Over time, the cumulative psychological dis-
tress related to fear of poor health outcomes can exacer-
bate and manifest as depressive symptoms. Future
studies, mapping exact distances and travel time, should
explore this finding further as there are no other studies
to compare our findings in SSA. In a prospective cohort
study of persons newly diagnosed with HIV infection
from the US, Bhatia et al. [38] found that depression was
associated with baseline poor access to care.
Table 3 Multivariable logistic regression analysis for correlates of depressive symptoms in adults living with HIV from coastal Kenya
Multivariable logistic regression analysis
Predictor variable aOR (95% CI) p-value
Age 0.97 (0.94, 1.00) 0.07
Sex
Female Ref
Male 0.72 (0.33, 1.57) 0.41
Any current chronic illness
No Ref
Yes 5.72 (2.28, 14.34) < 0.001
cART regimen
First line Ref
Second line 6.93 (2.34, 20.49) < 0.001
Clinic accessibility
Yes Ref
No 2.37 (1.14, 4.91) 0.02
Perceived HIV-stigma 1.10 (1.05, 1.14) < 0.001
BMI 0.94 (0.88, 1.01) 0.07
n of the final model 445
Goodness of fit statistic p = 0.79
Variance explained by the model pseudo-R2 = 16.1%
Notes: aOR adjusted odds ratio, 95% CI - 95% confidence interval, Ref reference category, cART combination antiretroviral therapy, BMI body mass index
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Participants who were on second-line cART regimen
relative to those on first-line regimen were nearly 7-
times more likely to have depressive symptoms. A
change from first-line to second-line is a major step and
is usually indicated because of cART toxicity or first-line
cART resistance (often due to adherence issues) [45].
Whichever the case, there is an underlying immunologic
failure which may trigger depressive symptoms when a
patient is informed.
Among PLWHA, previous studies within SSA [31, 46]
and outside [47, 48] have consistently found that per-
ceived HIV-related stigma is significantly associated with
greater symptoms of depression. Similarly, we found that
the risk of positive depression screen was 1.1-times higher
among participants who reported increased perceived
HIV-related stigma. HIV-related stigma may lead to poor
engagement with care and ultimately, worse health out-
comes [34]. Therefore, the need for comprehensive HIV/
AIDS awareness and stigma reduction intervention pro-
grammes – using multiple channels and targeting entire
communities – needs to be continually addressed.
This study has some limitations. The cross-sectional
study design limits any causal inference. Because of the
sampling approach and selection criterion, the study find-
ings may not be generalizable to the adult population liv-
ing with HIV who are not actively attending HIV-related
services/care and the elderly people (above 60 years) living
with HIV. We also used PHQ-9 as a depression screening
tool. As such, we only report the prevalence of depressive
symptoms and not clinical depression. Previous studies re-
port social support, CD4 cell count, and viral load as sig-
nificant correlates of depressive symptoms among
PLWHA [4, 46]. However, we did not collect information
on social support and data on CD4 cell count, and viral
load were missing from clinical records (our primary data
source for clinical information). Consequently, these were
not included in our analyses. Lastly, interviewer adminis-
tration of study instruments in a face-to-face format may
have introduced social desirability bias when asking par-
ticipants sensitive and/or personal questions, e.g. “over the
last 2 weeks, how often have you been bothered by
thoughts that you would be better off dead or of hurting
yourself in some way” item of the PHQ-9.
By recruiting a relatively large sample size, this study
was well powered to estimate the prevalence and investi-
gate factors associated with depressive symptoms among
PLWHA. Even though PHQ-9 was used as a depression
screener, it has been found reliable for use with PLWHA
in Kenya [22], and our psychometric results also support
the reliability of this tool.
Conclusion
This study found a high prevalence (14%) of moderate
to severe depressive symptoms among adults receiving
cART on the Kenyan coast. Integration of mental health
screening into HIV primary care in our setting and simi-
lar settings is highly recommended to facilitate treat-
ment or referral services. Where this has been initiated,
we call for a timely nationwide implementation given
the reported success of integration efforts in other low
resourced settings [41, 49]. Identification should target
PLWHA with comorbid chronic illnesses, those on
second-line cART regimen, experiencing HIV-related
stigma, having problems accessing HIV-related services
among other high-risk groups for elevated depressive
symptomatology.
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